tiprankstipranks
TipRanksStock Market NewsEOLS NewsSVB Securities Believes Evolus (EOLS) Won’t Stop Here
Blurbs

SVB Securities Believes Evolus (EOLS) Won’t Stop Here

In a report issued on July 11, Marc Goodman from SVB Securities maintained a Buy rating on Evolus (EOLSResearch Report), with a price target of $18.00. The company’s shares closed last Thursday at $13.72, close to its 52-week high of $14.34.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 1.1% and a 47.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Currently, the analyst consensus on Evolus is a Strong Buy with an average price target of $15.20.

See the top stocks recommended by analysts >>

Based on Evolus’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $33.91 million and GAAP net loss of $17.4 million. In comparison, last year the company earned revenue of $12.24 million and had a net profit of $6.4 million.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Read More on EOLS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More